ORIC
Oric Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$856.09M
P/E Ratio
—
EPS
$-1.39
Beta
1.06
52W High
$14.93
52W Low
$7.23
50-Day MA
$9.07
200-Day MA
$10.74
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Oric Pharmaceuticals Inc
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of cancers. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-148.72M |
| Operating Margin | 0.00% |
| Return on Equity | -42.60% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.02 |
| Price-to-Book | 2.06 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $103.52M |
| Float | $82.53M |
| % Insiders | 5.85% |
| % Institutions | 114.17% |
Historical Volatility
HV 10-Day
—
HV 20-Day
—
HV 30-Day
—
HV 60-Day
—
HV Rank
—
Analyst Ratings
Consensus ($19.93 target)
2
Strong Buy13
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026